Mometasone Furoate Market Size

Request Free Sample Copy

Report ID: 5507
Published Date: Jan 03, 2025
Report Format: PDF, PPT

Buy Now

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Mometasone Furoate Market size was over USD 1.07 billion in 2024 and is poised to exceed USD 2.64 billion by 2037, growing at over 7.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of mometasone furoate is evaluated at USD 1.14 billion.

The market is booming as a result of the rising uncontrolled asthmatic conditions, which affect both children and adults. According to a report by CDC, about 44% of children, and 60% of adults have uncontrolled asthma.

Additionally, there is a rising awareness and focus on skincare and overall well-being as people become more conscious of taking care of their skin and seeking professional advice when needed. This has surpassed the demand for dermatological treatments like mometasone. Also, the expansion of the aging population worldwide is contributing to the growth of the sector.

Browse key industry insights with market data tables & charts from the report:

Mometasone Furoate Market Size & Share, Growth Trends 2037

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of mometasone furoate is evaluated at USD 1.14 billion.

The mometasone furoate market size was over USD 1.07 billion in 2024 and is poised to exceed USD 2.64 billion by 2037, growing at over 7.2% CAGR during the forecast period i.e., between 2025-2037. The market growth is owing to rising uncontrolled asthmatic conditions, which affect both children and adults.

North America industry is likely to hold largest revenue share of 47% by 2037, propelled by surge in the number of awareness campaigns regarding psoriasis, coupled with the high prevalence of skin conditions like eczema in the region.

The major players in the market are Bausch Health Companies Inc., Glenmark Pharmaceuticals Limited, Vetoquinol USA, AstraZeneca plc, Intersect ENT, Hikma Pharmaceuticals, Medlab Pharmaceuticals Private Limited, AdvaCare Pharma, Dermocare Laboratories, Taro Pharmaceutical Industries Ltd., Kyorin Remedio Co., Ltd, Teikoku Seiyaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals., and others.